EP4007812A1 — Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
Assigned to Alnylam Pharmaceuticals Inc · Expires 2022-06-08 · 4y expired
What this patent protects
The present invention relates to RNAi agents, e.g ., double stranded RNA (dsRNA) agents, targeting the SERPINF2 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a SERPINF2 gene and to methods of preventing and treating a SERPINF2 - a…
USPTO Abstract
The present invention relates to RNAi agents, e.g ., double stranded RNA (dsRNA) agents, targeting the SERPINF2 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a SERPINF2 gene and to methods of preventing and treating a SERPINF2 - associated disorder, e.g. , a disorder associated with thrombosis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.